Daiwa Securities Group Inc. Trims Stake in IQVIA Holdings Inc. $IQV

Daiwa Securities Group Inc. reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 45,056 shares of the medical research company’s stock after selling 2,997 shares during the period. Daiwa Securities Group Inc.’s holdings in IQVIA were worth $10,156,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. State of Wyoming increased its holdings in IQVIA by 151.4% during the fourth quarter. State of Wyoming now owns 4,143 shares of the medical research company’s stock valued at $934,000 after buying an additional 2,495 shares during the last quarter. Lido Advisors LLC increased its holdings in IQVIA by 14.7% during the fourth quarter. Lido Advisors LLC now owns 4,721 shares of the medical research company’s stock valued at $1,064,000 after buying an additional 604 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in IQVIA by 89.6% during the fourth quarter. Sivia Capital Partners LLC now owns 7,235 shares of the medical research company’s stock valued at $1,631,000 after buying an additional 3,419 shares during the last quarter. Glassy Mountain Advisors Inc. purchased a new stake in IQVIA during the fourth quarter valued at approximately $4,005,000. Finally, WCG Wealth Advisors LLC increased its holdings in IQVIA by 103.1% during the fourth quarter. WCG Wealth Advisors LLC now owns 33,582 shares of the medical research company’s stock valued at $7,570,000 after buying an additional 17,047 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on IQV shares. Barclays raised shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research note on Friday, March 6th. Royal Bank Of Canada started coverage on shares of IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective for the company. Mizuho set a $215.00 price objective on shares of IQVIA in a research note on Monday, February 23rd. HSBC set a $210.00 price objective on shares of IQVIA in a research note on Wednesday. Finally, Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, IQVIA presently has a consensus rating of “Buy” and an average target price of $224.13.

IQVIA Price Performance

IQV stock opened at $183.56 on Friday. IQVIA Holdings Inc. has a 52 week low of $147.62 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a fifty day simple moving average of $172.12 and a two-hundred day simple moving average of $194.94. The firm has a market capitalization of $30.64 billion, a P/E ratio of 22.75, a price-to-earnings-growth ratio of 1.57 and a beta of 1.21.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter last year, the business earned $2.70 earnings per share. IQVIA’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.